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Abstract
Increasing evidence suggests that synaptic dysfunction is a core pathophysiological hallmark of neurodegenerative
disorders. Brain-derived neurotropic factor (BDNF) is key synaptogenic molecule and targeting synaptic repair through
modulation of BDNF signalling has been suggested as a potential drug discovery strategy. The development of such
‘‘synaptogenic’’ therapies depend on the availability of BDNF sensitive markers of synaptic function that could be utilized as
biomarkers for examining target engagement or drug efficacy in humans. Here we have utilized the BDNF Val66Met genetic
polymorphism to examine the effect of the polymorphism and genetic load (i.e. Met allele load) on electrophysiological
(EEG) markers of synaptic activity and their structural (MRI) correlates. Sixty healthy adults were prospectively recruited into
the three genetic groups (Val/Val, Val/Met, Met/Met). Subjects also underwent fMRI, tDCS/TMS, and cognitive assessments
as part of a larger study. Overall, some of the EEG markers of synaptic activity and brain structure measured with MRI were
the most sensitive markers of the polymorphism. Met carriers showed decreased oscillatory activity and synchrony in the
neural network subserving error-processing, as measured during a flanker task (ERN); and showed increased slow-wave
activity during resting. There was no evidence for a Met load effect on the EEG measures and the polymorphism had no
effects on MMN and P300. Met carriers also showed reduced grey matter volume in the anterior cingulate and in the (left)
prefrontal cortex. Furthermore, anterior cingulate grey matter volume, and oscillatory EEG power during the flanker task
predicted subsequent behavioural adaptation, indicating a BDNF dependent link between brain structure, function and
behaviour associated with error processing and monitoring. These findings suggest that EEG markers such as ERN and
resting EEG could be used as BDNF sensitive functional markers in early clinical development to examine target
engagement or drug related efficacy of synaptic repair therapies in humans.
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Introduction
The brain-derived neurotrophic factor (BDNF) and its receptor,
tropomyosin-related kinase receptor type B (TrkB) are widely
distributed in the human brain and play a significant role in
supporting neuronal structure and function. In vitro experiments
have shown that BDNF enhances synaptic transmission via
multiple mechanisms. BDNF modulates long term potentiation
(LTP) [1,2,3], and also promotes synaptic growth (i.e. synapto-
genesis) and synaptic functioning by increasing spine density,
axonal growth and branching, and facilitating the expression of
the synaptic proteins synaptophysin, synaptobrevin and synapto-
tagmin [4,5,6]. BDNF enhances spatial learning and memory in
rats [7], meanwhile pharmacologic and genetic deprivation of
BDNF yields impairments in learning and memory performance
in these animals [8]. Although BDNF is widely distributed in the
human brain, its expression is reduced in neurodegenerative
disorders including Alzheimer’s disease, Huntington’s disease and
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Parkinson disease [9,10,11,12,13,14]. The possible role of BDNF
in mood and psychiatric disorders, such as bipolar disorder and
clinical depression, has also been indicated by several studies (for
reviews see [15,16,17]). Therefore, therapeutic strategies aimed at
synaptic repair and regeneration may be a viable strategy as
disease-modifying treatment of neurodegenerative diseases (see
review by [18]; [14,16,19]).
Synaptic degeneration is a core pathophysiological hallmark of
neurodegenerative disorders. In Alzheimer’s disease (AD), there is
progressive synapse loss in the cortex and hippocampus [20,21]
and synapse loss has been shown to correlate with disease
progression [22] and with episodic memory impairments [20].
These findings are supported by pre-clinical studies where age-
dependent deficits in hippocampal long-term potentiation (LTP)
and hippocampus-dependent memory have been reported in AD
mouse models [23]. Beta-amyloid accumulation has been identi-
fied as a significant part of the pathogenesis of AD, leading to
synaptic loss and memory impairments [24]. BDNF has been
shown to exert neuro-protective effects against b-amyloid induced
neurotoxicity both in vitro and in vivo in rats [25], and to
ameliorate cognitive deficits caused by synaptic lesion in an animal
model of dementia [26]. Further, Nagahara et al. [19] have
demonstrated in different animal models including transgenic
mice, aged rats and aged primates, that BDNF administration
ameliorates behavioural and cognitive deficits by preventing cell
death and neuronal atrophy in neuronal circuits involved in AD.
The development of ‘‘synaptogenic’’ therapies depend on the
availability of BDNF sensitive markers of synaptic structure and
function enabling synaptic dysfunction and repair/regeneration to
be measured in clinical trials. A genetic variation in the human
BDNF gene, a single nucleotide polymorphism (SNP) at nucleotide
(G196A, rs6265) has been identified with in vitro experiments
demonstrating that the G196A transition mutation in the coding
region of BDNF results in a non-conservative amino acid
substitution (valine [Val] to methionine [Met]) at codon 66 in
the pro-domain of precursor BDNF protein. The Met variant is
associated with impaired dendritic trafficking of BDNF, segrega-
tion into regulated secretory vesicles and synaptic localization, and
decreased activity-dependent secretion of BDNF (18–30% de-
crease) [27,28]. The Val66Met polymorphism has enabled
investigation on potential markers of synaptic structure and
function associated with changes in BDNF in humans. Although
attempts to establish a direct link between the polymorphism and
neurodegenerative diseases have been inconclusive [18], cross-
sectional and longitudinal studies have demonstrated structural
and functional differences between the phenotypes. Structural
magnetic resonance imaging (MRI) have shown some evidence for
reduction in grey matter volume in the hippocampus, amygdala
and cortex in BDNFMet carriers [29,30,31,32]. These findings are
supported by a longitudinal study in healthy subjects showing
greater age-related reductions in hippocampal volume in the
BDNF Met allele carriers [33], and by a longitudinal study
reporting greater cognitive decline over 36 months in subjects with
high beta amyloid load carrying the Met allele [34]. This latter
interaction between the Met allele and high beta amyloid load (a
risk factor of Alzheimer’s disease) suggests that the polymorphism,
hence BDNF, might have an effect on disease progression.
Functional magnetic resonance imaging (fMRI) studies have
however yielded inconsistent findings. Some studies suggest that
BDNF Met carriers exhibit reduced hippocampal activation during
episodic memory encoding or retrieval compared with BDNF Val/
Val subjects [27,35], even when performance levels were matched
[35], but when effects on successful memory related activation
were examined, BDNF Met carriers showed a greater engagement
of the hippocampus and additional areas in medial temporal lobe
during encoding and retrieval, potentially suggesting neural
inefficiency in memory-specific networks [36]. Similarly, studies
examining synaptic activity using brain stimulation – methods
such as transcranial magnetic stimulation (TMS), transcranial
direct current stimulation (tDCS) or paired associative stimulation
(PAS) – revealed inconsistent findings and sometimes paradoxical
results regarding impairments in cortical excitability or plasticity in
BDNF Met carriers [37,38,39,40,41,42].
One potential explanation for the inconsistent findings across
studies might be that in most of the cases, Met carriers including
both Met/Met homozygote subjects and Val/Met heterozygotes
are compared to Val/Val homozygotes [43]. The Met/Met
genotype is relatively rare (,5%; [44]) and its occurrence might
vary across studies. If the number of met alleles, i.e. the ‘met load’
exerts stepwise effects on neuronal functioning, then balancing the
number of Met/Met subjects and Val/Met subjects is important.
In fact, evidence from a recent pharmacogenetics study in mice
suggests that the met/met homozygote variant yield significant
disadvantages in synaptogenesis in the prefrontal cortex induced
by the NMDA receptor antagonist ketamine, when compared to
mice that carry at least one of the val allele [45]. Furthermore,
stepwise decrease in performance on cognitive tasks tapping into
intelligence, processing speed and memory recall has been found
in elderly human subjects [46]. Therefore, in this present study, we
investigate whether ‘met load’ yields any systematic differences in
human neuronal activity underlying cognitive performance.
Electrophysiological methods measure the neuroelectric activity
in the brain and hence are likely to be the most sensitive in vivo
indicators of synaptic activity, neural network synchronization and
function. Compared to studies utilizing structural and functional
magnetic resonance imaging, relatively few studies have examined
the effect of the Val66Met polymorphism on electrophysiological
markers of neural activity and synaptic functioning. Resting
electroencephalography (EEG) experiments revealed a general
increase in slow-wave activity (theta and delta power) but a
decrease in fast wave activity (alpha power) in BDNF Met carriers,
suggesting an increase in inhibitory and/or a decrease in
excitatory synaptic activity in the cortex [47], in accordance with
earlier findings from in vitro and in vivo animal studies showing
that BDNF regulates both excitatory and inhibitory synaptic
functioning [5,48]. Similarly, studies using event related potentials
have also shown that BDNF Met carriers exhibit impairments in
various cognitive paradigms probing error processing (i.e.
decreased d frequency band total power and synchronization
during an error related negativity (ERN) task) [49] and attention
(i.e. P300 latency increase and amplitude reduction) [29,50].
As part of a larger investigation into the role of BDNF on
synaptic and neural network activity in humans, we focused our
investigation on electrophysiological markers including ERN,
Mismatch Negativity (MMN), resting EEG activity/synchroniza-
tion and P300. These EEG/ERP markers were selected because
they have been shown to be sensitive to the BDNF Val66Met
polymorphism [29,49,50], and/or impaired in neurodegenerative
disorders including AD (e.g. [51,52]). The ERN is an event related
potential (ERN) produced in response to processing errors (i.e.
when an event is worse than expected) [53,54]. It is argued that
the occurrence of a negative event, an error, elicits a dopaminergic
error-signal from basal ganglia to the anterior cingulate cortex
(ACC). The ACC then elicits the electrophysiological marker of
error processing, the ERN [55,56,57,58]. The ERN reflects
increased neural synchronization in the error-processing network,
which leads to the intensification of performance monitoring and
behavioural adaptation [49,59,60]. MMN is an ERP that provides
BDNF and Markers of Synaptic Activity
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a neurophysiological representation of the pre-attentive acoustic
change detection system (i.e. when the brain detects that an
established pattern in sensory input has been violated) [61,62]. It
signals a change (i.e. prediction error signal) from what was
expected (i.e. predicted) on the basis of the preceding auditory
environment based on a memory representation [63,64]. P300 is
an ERP elicited in response to target (i.e. P3b) or novel (i.e. P3a)
stimuli presented amongst standard stimuli in an oddball paradigm
[65]. The P3a is thought to reflect an alerting process (i.e. focal
attention) while, the P3b is thought to reflect context updating and
working memory processes (for reviews see, [65,66]). Resting EEG
oscillations signify the intensity and synchrony of neural activity
(i.e. EEG power) across various frequency bands. Fast wave
oscillations (alpha frequency, ,8–12 Hz) are associated with
cortical excitatory mechanisms while slow-wave oscillations (delta,
,0.5–3.5 Hz and theta frequency, ,4–7 Hz) reflect cortical
inhibition mechanisms; these mechanisms are maintained and
balanced via homeostatic regulations within cortico-thalamical
networks in the idling brain [67,68].
Hence, the aim of the study was to examine the effect of the
BDNF Val66Met polymorphism and the effect of Met allele load (i.e.
the number of Met alleles) on changes in synaptic activity as
measured by ERN, resting EEG oscillations, mismatch negativity
(MMN), and P300. As the electrophysiological investigation was
part of a larger study examining the effect of the polymorphism on
other markers (i.e. hippocampal activity during declarative
memory (fMRI), brain structure (MRI) and cortical excitability
(Transcranial Direct Current Stimulation (tDCS)), we also briefly
report these effects for comparison of effect sizes. The detailed
findings on these markers will be reported and published
elsewhere.
Methods
Ethics statement
The study was approved by Cambridge South National
Research Ethics Committee (REC reference 11/EE/0360).
Participants provided written consent to participate in the study.
The consent procedure was approved by the Cambridge South
National Research Ethics Committee.
Subjects
Sixty healthy, right-handed volunteers participated in the study
(39 males; mean age: 40.5 yrs, rage: 19–55 yrs). Twenty partic-
ipants were homozygous for the met allele (Met/Met), 20 were
heterozygous (Val/Met), and 20 were homozygous for the val
allele (Val/Val). Subjects for the study were recruited from a
database of approximately 10,000 subjects with information on the
BDNF gene polymorphism, held at the Phase I GSK Clinical Unit
and the Cambridge BioResource, Cambridge Biomedical Re-
search Centre (CBRC). Level of education across the three groups
is reported in Table S1 (File S1). Level of education was
comparable across the three groups. Participants went through a
thorough screening procedure before entering the study, whereby
subjects with a history of Axis I psychiatric disorders, neurological
disorders, any medical condition or illness affecting their
participation, alcohol or substance abuse, pregnancy, were
excluded from study participation (for more details on recruitment,
exclusion criteria, and procedure see [69]). Participants were also
non-smokers and free of any medication.
Genotyping
DNA was extracted from blood samples via standard methods
and genotyped for the BDNF Val66Met SNP via TaqMan
50exonuclease assay (Applied Biosystems, Foster City, CA, USA)
(described in more detail in Teo et al., [86]). Subjects were all
Caucasian except one who was of mixed ethnicity. The genotypes
in this sample are not in Hardy-Weinberg Equilibrium. This was
intentional – an equal number of subjects was recruited from each
of the genotype groups in order to look at gene-dose effects in a
balanced design.
Procedure
After a through screening session selecting volunteers eligible for
the study, volunteers attended two separate testing sessions on two
separate days. EEG and MRI measurements were performed as
part of a wider study examining a variety of neurophysiological
and behavioural endpoints, but only the EEG and the structural
MRI data are reported here in detail. Subjects arrived at the GSK
Clinical Unit in the morning and a urine drug screen and alcohol
breath test was performed followed by EEG assessment. MRI
scanning was performed between 12.30 and 14.30 hours. The
study was double-blind.
Experimental paradigms
Error-related negativity (ERN). The flanker task, an
established paradigm for exploring the behavioural and neural
correlates of error processing [70,71], was used to generate the
ERN.
Figure S1 illustrates the task procedure and stimuli. Partici-
pants were asked to indicate the direction of the target arrow
(middle) as soon as possible after it has appeared between the two
flanker arrows. Flanker and target can be congruent (i.e. flankers
pointing into the target’s direction), incongruent (flankers point to
the opposite direction), and neutral. Subjects tend to commit more
errors on incongruent trials and also tend to slow down after an
incorrect response (‘post-error slowing’; [72]). Recent accounts of
post-error slowing hold that it reflects attentional orientation
associated with violation of expectations [72], and with behav-
ioural adaptation processes [49,73]. The magnitude of post-error
slowing is thought to index the strength of the error monitoring
response [74]. The electrophysiological marker of error process-
ing, the error-related negativity (ERN; [54]) is observed when
response-locked ERPs for error trials are compared to correct
trials.
Stimuli were presented using Neuroscan Stim2 system with
visual stimuli delivered to a CRT monitoring a darkened room.
Participants seated comfortably in front of a 75 Hz, 17" CRT
monitor positioned approximatelly 95 cm away from their eyes.
Participants were asked to indicate the direction of the target
(middle) arrow as fast as possible with a button press using their left
or right thumb. Reaction times (RT) and error rates were
recorded.
Error rate (%) was calculated as the ratio of erroneous
responses. Post-error slowing (PES), an index of error processing
[49], was calculated as the difference between RTs following
erroneous responses and RTs following correct responses. PES was
also corrected for general speed (PES divided by mean reaction
time); so that possible differences in general speed between groups
would not yield group differences in PES.
Resting state EEG. Approximately 7.5 minutes of EEG data
were recorded during resting, with eyes closed. Participants were
asked to close their eyes and to relax but to not move or fall asleep.
Target P3 (P3b) and Novelty P3 (P3a). An ‘‘oddball’’
paradigm [75] with three different tones was used to elicit the
P300 and P3a ERP components. The ‘standard’ stimuli were
1000 Hz tones occurring with 85% probability. The ‘target’
stimuli were 2000 Hz tones occurring with 7.5% probability. The
BDNF and Markers of Synaptic Activity
PLOS ONE | www.plosone.org 3 April 2014 | Volume 9 | Issue 4 | e95558
‘novel’ stimuli were white noise, occurring with 7.5% probability.
The ISI ranged between 1000 and 2200 ms, randomised in
100 ms steps. Subjects were asked to listen to the tones and
indicate with a button press when they heard the ‘target’ (but
ignore the ‘novel’) sound. Tones were played binaurally through
ear inserts at 80 dB.
Mismatch negativity (MMN). Subjects were seated com-
fortably in front of a CRT monitor and asked to watch scenes from
a wildlife documentary without sound. Tones were played
binaurally through ear inserts at 80 dB. Duration deviants with
roving frequency design were used to generate MMN. Standard
tones were 50 ms long and deviant tones were 100 ms long, with
the latter presented at the end of a train of standard tones of 12–15
in length. Tones were separated by an ISI of 350–450 ms,
randomised in 10 ms steps. Between each train of standard/
deviant stimuli, one to two new mask tones were presented. Each
train was presented at a different frequency, separated from the
previous train by at least 500 Hz (tone range 500–5000 Hz).
EEG recording and analysis
EEG was recorded using a Neuroscan Synamps2 EEG amplifier
using a 64 channel QuickCap with integrated sintered Ag/AgCl
electrodes, reference electrode located between Cz and CPz.
Additional individual electrode wires were placed bilaterally on the
outer canthi and above and below the left eye to record the EOG.
An individual electrode wire was placed on the nose to use as a re-
reference electrode for the MMN paradigm. Electrode impedanc-
es were below 10 kOhms at the start of the recording. Bioelectric
signals were amplified in AC mode with a 24 bit ADC providing
3nV/bit resolution. EEG was recorded with 0.3 Hz high pass and
200 Hz anti-aliasing filters and sampled at 1000 s/s. Responses
were captured through a 4 button response pad (part of the
STIM2 system) with a 1 ms response accuracy.
Data pre-processing and artefact rejection were performed
offline using Neuroscan Curry7 Neuroimaging Suite. Eye move-
ment correction was performed by PCA. Epochs containing
activity 6100 mV were excluded from further analyses. Six
subjects’ data were discarded from the ERN analysis (two from
each genetic group) because after artefact rejection there were only
a low number of error trials (,5%) in their data. Further EEG
analyses were carried out in MatLab (MathWorks).
Error-related negativity, time-domain analysis. Offline
data were re-referenced to the average electrode and a second-
order lowpass (80 Hz) Butterworth filter (corresponding to 12 dB/
octave rolloff) was applied. For the time-domain ERP analysis the
data was further smoothed with a 51 point long moving average
filter in order to remove high-frequency noise from the ERP
waves. This filtering did not affect the frequency spectrum for
time-frequency analyses. Data were then epoched into 3000 ms
long segments time-locked to responses (21500 ms to +1500 ms
around error or correct response markers at time point zero).
Epochs were baseline corrected to the 2800 to 2600 ms interval
[49]. Time-domain ERPs were then truncated to the 2800 to
800 ms interval. Event-related potentials (ERPs) evoked by correct
responses were averaged together within each subject to create the
correct response negativity (cN). Similarly, ERPs evoked by error
trials were averaged together to create the error-related negativity
(ERN). Difference waves were created by subtracting the correct
from the erroneous waveforms within each participant. Following
the visual inspection of the mean ERPs, peak amplitudes and peak
latencies of cN, ERN, and difference waves were automatically
detected within the 0–200 ms post-stimulus window. Data from
electrode FCz is presented and submitted to further analysis, since
the effect was the strongest at this location (see the time-domain
ERP results and also [49]).
Error-related negativity, time-frequency analysis. Follow-
ing up the time-domain ERN analysis, time-frequency power and
phase-locking (PL) analyses were performed on all trials (i.e. trial-by-
trial analysis) using short-time Fourier transforms with Hanning
window tapering, resulting in a time-frequency landscape with a
resolution of ,3 ms in time and 0.49 Hz (from 0.5 to 30 Hz) in
frequency. For the time-frequency analysis scripts from the
Figure 1. Behavioural results of the flanker task. Panel A: Raw RTs following correct and error responses for the three genetic groups. Panel B:
Post-error slowing expressed in raw RTs (RT following error minus RT following correct responses). Panel C: Post-error slowing, corrected for general
speed ([RT following error - RT following correct]/meanRT). *: p,0.05. Bars represent standard error.
doi:10.1371/journal.pone.0095558.g001
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EEGLAB toolbox [76] were used. Three thousand millisecond-long
(3000 datapoints) epochs were used for the decomposition. Based on
the topographical location of the time-domain ERN, and following
earlier findings in the literature [49], data from the FCz electrode
were analysed and presented.
Resting state EEG. EEG was epoched into approximately 4
second segments (4096 samples).
Data were transformed using fast Fourier Transform. Average
power in the defined frequency bands of 0.5–3.5 (delta), 4–7.5
(theta), 8–11.5 (alpha), 12–29.5 (beta), 30–80 Hz (gamma) and
0.5–80 Hz as total power across all bands were calculated.
Data from individual electrodes were grouped according to
topographical regions based on their anatomical location and were
averaged together and were analysed as whole regions. Regions
were Frontal (Fp1, Fpz, Fp2, AF3, AF4, F7, F5, F3, F1, Fz, F2, F4,
F6, F8), Central (FC3, FC1, FCz, FC4, C3, C1, Cz, C2, C4, CP3,
CP1, CPz, CP2, CP4), Temporal (T7, TP7, P7, T8, TP8, P8) and
Parieto-occipital leads (P3, P1, Pz, P2, P4, PO3, POz, PO4, O1,
Oz, O2) were averaged together and were analysed as whole
regions.
Target P3 (P3b) and Novelty P3 (P3a). Offline data were
re-referenced to the linked mastoids and a second-order lowpass
(30 Hz) Butterworth filter (corresponding to 12 dB/octave rolloff)
was applied. Data were then segmented into 900 ms long epochs,
time-locked to the stimuli (100 ms before stimuli and 800 ms after
stimuli). Epochs were baseline-corrected to the 2100 to 0 ms
interval. ERPs evoked by ‘target’ tones were averaged together to
form the P3b ERP component and ERPs evoked by ‘novel’ stimuli
were averaged together to form the P3a ERP component. Peak
amplitude and latency of the P3b within the time window of 200–
800 ms was measured at the CPz electrode. Peak amplitude and
latency of the P3a within the time window of 200–500 ms was
measured at the Cz electrode. Time windows and examined
electrodes were selected based upon where these peaks are the
most prominent [65].
Mismatch negativity (MMN). Data was re-referenced to
the nose electrode. Epochs of 2100 ms to 500 ms time-locked to
stimulus presentation were extracted. Epochs were baseline-
corrected to the 2100 to 0 ms interval. Responses to standard
stimuli at all train positions (with the exception of position 1) were
averaged together to create the standard average wave. Responses
to deviant stimuli were averaged to create the average deviant
wave. The standard was then subtracted from the deviant response
to create the difference waveform. Data from the Fz electrode was
analysed [77].
Statistical analyses
Group differences, experimental condition effects (in the flanker
task), and their potential interactions were tested with analysis of
variance (ANOVA). Age and gender were entered as covariates to
the analyses. Post-hoc pairwise comparisons, corrected for multiple
comparisons (Tukey-Kramer correction) were performed when
appropriate. For group comparisons, two different genetic models
were considered: (1) the met-dominant model, where Met carriers
are grouped together and compared against Val/Val homozygotes
(this model is the most prominent in the literature); and the (2)
additive model, where the three genotype groups were entered
into ANOVA separately in order to test whether there were
stepwise effects due to ‘met load’. Outliers, who fell outside three
standard deviations from the mean, were excluded from further
analyses. All the relevant variables were normally distributed
(according to the Kolmogorov-Smirnov test, all p.0.2). Only
behavioural error rates and the latency of the ERN peak following
correct responses were not normally distributed according to the
test. Fisher’s z-transform was applied to the error rate data.
Latencies after correct responses were not relevant for the analysis.
Effect sizes (partial eta squared) for the comparability of different
measures and platforms are also reported. We report partial eta
because this measure is one of the most common measures of effect
size used in factorial ANOVA designs and also recommended in
neuroscience research [78].
Primarily, we report p-values for each measure uncorrected for
multiplicity. In addition, for each platform where at least one p,
0.05 was observed, we applied the false discovery rate (FDR)
procedure as described by Benjamini and Yekutieli to allow for
dependency between test statistics [79], to confirm the FDR within
each platform was controlled at 5%.
Structural MRI data acquisition and pre-processing
MR images were acquired on a 3T Siemens TimTrio at the
Wolfson Brain Imaging Centre, University of Cambridge.
Structural data were acquired with a sagittal MPRAGE T1-
weighted, three-dimensional, inversion recovery gradient echo
sequence with the following parameters: Inversion time = 900 ms;
echo time = 2.98 ms; repetition time = 2300 ms flip angle = 9
degrees; voxel dimensions = 1 mm61 mm61 mm. Acquisition
time = 9.14 mins.
Structural data was analysed with FSL-VBM [80], an optimised
VBM protocol [81] carried out with FSL tools [82]. Firstly,
structural images were reoriented to standard space, brain-
extracted and grey matter-segmented before being aligned to the
MNI 152 template [83]. MNI 152 alignment involved affine
registration of grey matter images to GM ICBM-152 to create a
first pass affine template; non-linear re-registration of native grey
matter images to the affine template was then performed.
Resulting warped images were averaged and flipped along the x-
axis in order to create a left-right symmetric, study-specific grey
matter template. To avoid bias in the form of favouring one group
over another during registration, all subjects from contrasting
groups were included in the template construction process.
Secondly, all native grey matter images were non-linearly
registered to the study-specific template and modulated to correct
for local expansion and contraction due to the non-linear
component of the spatial transformation. Modulation was
achieved by multiplication of each voxel of each registered grey
matter image by the Jacobian of the associated warp field. Finally,
modulated grey matter images were smoothed with an isotropic
Gaussian kernel with a sigma of 3 mm. To calculate ACC and
PFC volumes, the AAL atlas was employed as a mask for summing
then averaging underlying warped and modulated grey matter
image intensities.
Statistical analysis of structural MRI data. Voxel-wise
GLM statistical analysis was performed across the whole-brain
using CamBA v2.3.0 (http://www-bmu.psychiatry.cam.ac.uk).
The location of clusters of interest was established using CamBA
derived spatial information. The independent variable was a linear
contrast across met-loading or a met-dominant model as described
above. Sex, age and total intracranial grey matter volume were
added as regressors. Estimates of the linear effect size divided by its
associated standard error were tested for significance using a
permutation method at the cluster level, correcting for multiple
comparisons across clusters. All results are reported at a
significance level of ,1 false positive cluster per image [84].
Using significant voxel clusters as masks, mean cluster intensities
were extracted from modulated standard space grey matter images
for all subjects then correlated with behavioural data using SPSS
(v17).
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Results
Demographics
There were no significant age or gender differences among the
genetic groups (age: F(2,57) = 0.5, p.0.6, gender: H(2,
N= 60) = 0.9, p.0.6. Mean age: 41.8, 40.5, and 38.5 years;
males: 10, 15, and 14, for Met/Met, Val/Met, and Val/Val
respectively. Group differences in age and gender remained non-
significant after removing 6 subjects’ data from the ERN analysis,
both p.0.3).
Behavioural results and error-related negativity in the
flanker task
Behavioural data – Reaction times (RT). Correct and
error RTs were entered into a two-way mixed design ANOVA
with Response Type (Correct vs. Error) as within-subject and
Group as between-subject factor. Correct RTs were significantly
slower than erroneous RTs (427.8 ms, SE: 3.9 and 355.4, SE: 3.9
for correct and error RTs, respectively. F(1,58) = 10.76, p = 0.001,
g=0.39). There was no main effect of group (both genetic models
p.0.3) and no interaction of response type and group (all p.
0.15).
Behavioural data – Error rates (%). Error rates in
congruent and incongruent conditions were entered into a two-
way mixed design ANOVA with Condition as within-subject and
Group as between-subject factor. The main effect of Condition
was significant (0.8%, SE: 0.12 and 13.7%, SE: 1.5, for congruent
and incongruent conditions, respectively. F(1,58) = 13.83, p,
0.001, g=0.44). Examination of the different genetic models did
not yield significant differences in error rates (both p.0.26) or the
modulation of the Condition effect by group (both p.0.18).
Behavioural data – Post-error slowing. Post-error slowing
values were entered into a one-way ANOVA with Group as
between-subject factor. Both the linear model (F(2,57) = 2.27,
p = 0.038, g=0.26) and the met-dominant model were significant
(F(1,58) = 3.99, p = 0.05, g=0.25). The post-error slowing is
shown in Figure 1/A. The linear model best explained the data.
In order to investigate the source of the post-error slowing, post-
hoc pairwise comparisons were performed on RTs following
correct and erroneous responses within and across genetic groups.
As Figure 1/B shows, the post-error slowing (i.e. the difference
between post-correct and post-error RTs) was significant only in
the Val/Val group (p = 0.004), while it was not significant in the
Val/Met (p = 0.39) and in the Met/Met (p = 0.71) groups.
Time-domain ERP data. The amplitude and latency of the
error-effect, the error-related negativity (ERN) expressed as the
difference between error and correct responses, were subjected to
a one-way ANOVA with Group as between-subject factor.
Significant group differences were further explored using post-
hoc comparisons among correct and error responses within and
between genetic groups (corrected for multiple testing) are
performed to investigate the source of the ERN.
Neither the ERN peak amplitude nor the ERN peak latency
was significantly different among the genetic groups; neither of the
genetic models were significant (both p.0.27). In order to make
sure that the differences in referencing would cause different
results, laplacian transformation (following Beste et al. 2010 [49])
has also been performed on the data. Neither of the genetic models
were significant on the transformed data (both models’ p.0.8;
mean and SE: 250.62 (10.3) mV/m2, 258.7 (9.98) mV/m2, and 2
59.3 (30.86) mV/m2 for Met/Met, Val/Met and Val/Val groups
respectively). Waveforms for error and correct responses and their
difference wave (ERN) per groups are illustrated in Figure 2.
Time-frequency domain data. Based on the localization of
the ERN component (see Figure 2) and on previous literature [49],
time-frequency data from the FCz electrode were analysed. Mean
ERSP peak values and PLF values of the difference spectrum in
the delta (0.5–4 Hz) frequency band within the post-response time
interval (0–250 ms) were subjected to a one-way ANOVA with
Group as between-subject factor. The time-frequency ‘region of
interest’ was a priori defined based on visual inspection of the data;
which range approximately corresponds to earlier findings [49].
Significant group effects were further explored using pairwise
comparisons (correcting for multiple testing) between correct and
error responses within and across genetic groups.
Event-related spectral perturbation (ERSP) (i.e.
Power). Examination of the genetic models yielded a significant
met-dominant model (F(1,52) = 4.5, p = 0.038, g=0.29) (the linear
model did not reach significance: p = 0.1).
Pairwise comparisons (corrected for multiple testing) of response
type (correct and error) within and between genotype groups
indicated that the above effect was due to significantly different
error processing between Met carriers and Val/Val group. As can
be seen in Figure 3/A, the effect of response type (i.e. correct
versus error ERSP) was significant in both the Met carriers and in
the Val/Val groups (p,0.001 for both). However, ERSP following
error responses in the Val/Val group was significantly larger than
ERSP following error responses in the Met carriers (p,0.001;
Mean and standard error: 4.2 (0.54), 2.8 (0.4) for Val/Val and Met
carriers, respectively). There were no difference in correct ERSP
between the two groups (p = 0.99), indicating that the group
differences were due to lower ERSP specifically in the error
condition in met carriers.
Phase-locking factor (PLF). Similar to the ERSP data,
examination of the different genetic models yielded a marginally
significant met-dominant model in the difference PLF (error-
correct) (F(1,52) = 3.72, p = 0.059, g=0.26; the linear model was
not significant: p.0.15), indicating that the error-effect is
modulated by the polymorphism (see Figure 3/B). Pairwise
comparisons (corrected for multiple testing) of PLF following
correct and PLF following error responses between and within
Met carriers and Val/Val subjects revealed a significant effect of
response type in both groups (correct versus error: both p,
0.0002). Similar to the ERSP results, the group difference in the
error-related PLF was due to significant differences specifically in
the error condition. Val/Val participants showed significantly
larger phase-locking (mean and standard error: 0.78 (0.03)
following error responses compared to Met carriers (0.65 (0.026))
(p,0.005), while there was no group difference between groups in
PLF following correct responses (p = 0.98).
Grey matter volume
Anterior Cingulate and prefrontal cortex. Examination of
the different genetic models revealed significant whole-brain tested
differences in grey matter volume located around the ACC, with
the linear model explaining the data slightly better (linear:
F(2,55) = 8.43, p,0.001, g=0.48; met-dominant: F(1,56) = 8.4,
p,0.005, g=0.31 from data extracted from significant clusters).
Further, a significant PFC GM volume loss has also been found in
Met carriers (linear: F(2,55) = 3.34, p = 0.04, g=0.1; met-domi-
nant: F(1,56) = 3.02, p = 0.087, g=0.22 again from data extracted
from significant clusters). Figure 4 illustrates the group differences
in grey matter volume.
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Correlations among error-related processes and Anterior
cingulate grey matter volume
In order to reveal structural-functional relationships among
behavioural and electrophysiological measures of error-processing
and brain structure, endpoints showing significant genotype effects
were subjected to correlational analyses. We were interested in the
relationships among brain structure (grey matter volume), brain
function and neuronal activity measured by ERSP and PLF, and
behavioural function measured by post-error slowing. The results
are summarized in Table 1. First, correlations between post-error
slowing and 1) anterior cingulate grey matter volume, 2) prefrontal
cortex grey matter volume, 3) ERSP following error responses, and
4) PLF after error responses were investigated. Second, correla-
tions between anterior cingulate grey matter volume and 1) ERSP
following error, and 2) PLF following error were investigated.
Third, correlations between prefrontal cortex grey matter volume
and 1) ERSP following error, and 2) PLF following error were
tested.
Post-error slowing showed significant correlations with anterior
cingulate grey matter volume in Met/Met subjects but not in the
other two groups (Val/Met and Val/Val); the larger the ACC
volume, the larger the post-error slowing in Met/Met subjects.
Furthermore, ERSP following error responses also significantly
predicted post-error slowing in the Met carriers but not in Val/Val
subjects. The significant correlations are shown in Figure 5.
Correlation coefficients were compared in order to see whether
beyond the significance of the relationships, the strengths of the
above indicated relationships are statistically different between the
groups [85,86]. The correlation between ACC grey matter volume
and post-error slowing was indeed significantly stronger in Met
carriers than in Val/Val participants (z-score = 2.097, p,0.036).
For the correlation between ERSP and post-error slowing,
although the ERSP was significantly predictive of post-error
slowing in Met carriers but not in Val/Val subjects, the difference
of the correlation values were not significant (z-score = 0.28, p.
0.7). It indicates that the nature of the relationship between delta
Figure 2. Time-domain ERN results. Panel A: Waveforms for correct (grey) and error (black) responses (FCz), for each group. Panel B: ERN wave for
the three genetic groups. Panel C: Topographic plots of the ERN peak (40–100 ms). Electrode FCz is marked with disk.
doi:10.1371/journal.pone.0095558.g002
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power and post-error slowing are not different, but somewhat
stronger in Met carriers.
Resting state EEG
Absolute power. Examination of the different genetic models
revealed significant group differences in the theta (4–7 Hz)
frequency band during resting state. The met-dominant model
explained the data significantly over frontal, central, temporal and
parieto-occipital regions (all Fs(1,55).4.9, p,0.03, g,0.28). Met
carriers, especially the Val/Met group, showed increased activity
in the theta band, compared to Val/Val subjects. The group
differences are illustrated in Figure 6.
No significant group effects emerged in the other (delta, alpha,
beta, gamma) frequency bands (all p.0.07). Results for all bands
and regions are summarized in Table S2 (File S1).
Relative power. The analysis of relative power, correcting
for the possible general, total power differences among groups,
confirmed the significant met-dominant model in the theta power
(parieto-occipital: F(1,55) = 6.1, p,0.02, g=0.32; and strong
statistical trend for frontal, central and parietal regions: all p,
0.07, g.0.22). No other significant differences emerged in the
other frequency bands (all p.0.07).
P300 and MMN. The analysis of P3a and P3b ERP
components, and of the MMN, yielded non-significant results.
The MMN, P300 and P3a peak amplitudes and latencies are
presented in Table S3 (File S1).
In the study, endpoints from the other different platforms
(fMRI, TMS, cognitive tests) have been analysed and reported in
detail elsewhere [69,87]. In order to illustrate the distribution of
endpoints across all platforms, effect sizes and corresponding p-
values for all the endpoints are shown in Figure 7 (and Table 2).
As can be seen in Figure 7, a few of the EEG endpoints and
anterior cingulate grey matter form a cluster in the upper end of
the distribution, indicating that these endpoints were sensitive to
the polymorphism. In addition, for each platform where at least
one p,0.05 was observed, we applied the false discovery rate
(FDR) procedure [79], to confirm the FDR within each platform
was controlled at 5%. Endpoints remaining significant after the
FDR correction are indicated in Figure 7. Namely, endpoints
with p,0.008 remain significant after the correction (phase-
Figure 3. Behavioural results of the flanker task. Panel A: Event-related spectral perturbation (ERSP) during correct and error responses, and
their difference (error-correct) for the three genetic groups. Boxes in the time-frequency plots indicate the time-frequency interval from which the
values have been submitted to statistical analyses. Statistics are illustrated in the lower graph, bars represent standard error, **:p,0.005. Panel B:
Phase-locking factor (PLF) values, as above. *:p,0.05.
doi:10.1371/journal.pone.0095558.g003
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locking following errors in the theta band, EEG resting state
power, and anterior cingulate grey matter volume).
Discussion
In this study we aimed to develop and validate markers of
synaptic activity that are sensitive to BDNF-related synaptic
plasticity and could be utilised in clinical trials to test the efficacy of
‘‘synaptogenic’’ therapies in development for neurodegenerative
disorders. Taking advantage of the BDNF Val66Met polymor-
phism in humans, we examined the effects of the polymorphism on
brain activity and behaviour in healthy subjects using a variety of
methods including fMRI, MRI, tDCS, EEG/ERP and behavioral
testing. The objective of the study was twofold. First, we tested
potential biomarkers of synaptic functioning which have previously
Figure 4. Anterior cingulate and prefrontal cortex grey matter volumes. Panel A: Met/Met vs Val/Val contrast. Significant cluster are
rendered onto an average brain in MNI standard space. Panel B: Extracted anterior cingulate grey matter volume for each group. Panel C: Extracted
prefrontal cortex (left) grey matter volume for each group. Bars represent standard error.
doi:10.1371/journal.pone.0095558.g004
Table 1. Correlations.
Var 1 Var 2 Met/Met Val/Met Met-carriers Val/Val
PE slowing ACC GM r = 0.67 r = 0.16 r = 0.36 r =20.36
p=0.003** p= 0.51 p= 0.03* p=0.15
PFC GM r = 0.14 r = 0.03 r = 0.07 r =20.26
P = 0.59 p = 0.91 p = 0.68 p = 0.29
ERSP error r = 0.22 r = 0.49 r = 0.38 r = 0.29
p = 0.4 p= 0.0546 p= 0.027* p=0.28
PLF error r =20.06 r = 0.06 r = 0.097 r = 0.25
p = 0.83 p = 0.8 p = 0.69 p = 0.34
ACC GM ERSP error r = 0.34 r = 0.25 r = 0.11 r =20.1
p = 0.19 p = 0.35 p = 0.54 p = 0.7
PLF error r =20.18 r = 0.08 r =20.08 r =20.15
p = 0.53 p = 0.77 p = 0.72 p = 0.56
Columns Var1 and Var2 contain the two variables correlated with each other in the given line. First section: Var1 is Post-error slowing. Second section: Var1 is anterior
cingulate grey matter volume. R-values and corresponding p-values are reported for the three genetic groups and for the met-carriers combined. Significant
correlations are marked with bold italic typesetting.
u:p,0.06,
*:p,0.05;
**p,0.005.
doi:10.1371/journal.pone.0095558.t001
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been associated with the BDNF Val66Met polymorphism. Replica-
tion of significant markers will serve us in establishing the most
sensitive and reliable tools for future research into ‘synapse repair’
strategies in the prevention and treatment of neurodegenerative and
psychiatric disorders utilizing BDNF. Second, we systematically
tested the effect of ’met allele load’ across all the significant
endpoints in order to reveal whether the relatively rare met
homozygotism (,5%) was responsible for the great variability in
findings in the literature. In this report we primarily focus on the
electrophysiological markers of synaptic activity as some of these
markers have been found to be the most sensitive to group
differences associated with the genetic polymorphism. However,
comparisons were also made with markers in terms of effect size to
highlight the greater sensitivity of some of the electrophysiological
markers. The detail of the findings on the other markers will be
reported and published elsewhere [69,87].
Across the different platforms and various endpoints, some of
the electrophysiological measurements proved to be the most
sensitive markers of synaptic functioning affected by the BDNF
Val66Met polymorphism (as illustrated in figure 7). Met carriers
showed decreased neural activity and neural synchrony in
response to errors (delta band power and PLF), showed decreased
post-error slowing, showed increased low frequency activity during
resting compared to Val homozygotes. Although similar correc-
tions are not commonly done in neuroscience research, it is
interesting to note that the ERN phase locking factor, the resting
state EEG theta power measures, and the anterior cingulate grey
matter volume remain significant after correction of multiplicity;
although, some of the endpoints (behavioural post-error slowing
(i.e. number 57 in Figure 7) and ERN delta power (number 61
and 62)) do not remain significant (see Figure 7). The ERN
findings replicate a previous study by Beste et al. [49]. Specifically,
Figure 5. Correlations between grey matter and post-error slowing and between grey matter and ERSP. Panel A: Correlation between
anterior cingulate grey matter volume and post-error slowing for met-carriers and Val/Val group. Met/Met subjects are filled dots, Val/Met subjects
are empty dots in the Met-carriers plot. Dashed line indicates 95% confidence interval of the linear regression. Panel B: Correlation between error
ERSP and post-error slowing, as above.
doi:10.1371/journal.pone.0095558.g005
Figure 6. Topographic plots of power in the theta frequency band. Graph represents averaged values for central, frontal, temporal and
parieto-occipital regions, per each genetic group. Bars represent standard error. * p,0.05;u p,0.06 according to post-hoc Tukey-Kramer comparisons
(Val/Met vs Val/Val).
doi:10.1371/journal.pone.0095558.g006
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we have replicated that Met carriers showed reduced or absent
post-error slowing in a flanker-task. The reduced or lacking post-
error slowing is suggestive of deficiencies in behavioural adapta-
tion following the commission of errors in Met carriers. We have
also replicated that the power and phase-locking in the delta
frequency band following errors was reduced in Met carriers,
compared to Val/Val subjects. These results signify the altered
functioning of the neuronal network subserving error monitoring
and behavioural adaptation in Met carriers [49]. Furthermore, in
the latter study, phase-locking in the delta band was shown to
predict post-error slowing and the authors concluded that stronger
neural activity and synchronization mechanisms are associated
with elevated behavioural adaptation [49,59]. In our data, neural
dynamics in the delta frequency band also predicted behavioural
post-error slowing. However, in contrast to the previous findings
[49], we observed that delta power, and not phase-locking,
predicted post-error slowing. The reason for this discrepancy is
unclear, but may be due to the unavoidable variability and noise
inherent to different neuroscience laboratories and to datasets
drawn from different groups. But importantly, reduced post-error
slowing, reduced delta band power, and reduced delta band
phase-locking in Met carriers has now been consistently observed
suggesting that the BDNF Val66Met polymorphism modulates the
functioning of the neural network supporting error processing and
behavioural adaptation. Interestingly, abnormalities in ERN have
also been reported in neurodegenerative disorders including basal
ganglia disorders (Parkinson’s and Huntington’s disease;
[88,89,90,91,9]. Hence ERN may represent both a BDNF and
disease relevant marker that could be used to monitor changes in
synaptic activity in clinical trials.
In addition, accompanying the alterations in neuronal func-
tioning, significant differences in the structure within this network
have also been shown. Reduced grey matter volume in the
anterior cingulate has been previously reported in Met carriers
[31,92]. As can be seen in Figure 7, ACC grey matter volume
was among the strongest markers sensitive to the BDNF
Figure 7. Effect sizes. P-values (log scale) (X-axis) and corresponding effect sizes (Y-axis) for the met-dominant model for every endpoint. Dotted
vertical line marks the alpha level (0.05): endpoints falling on the right side are considered to be statistically significant (i.e. p,0.05). (*) indicates
significant endpoints after FDR correction (all adjusted p,0.04). Different platforms are marked with different colours, for further details see Table 2.
P-value transform: - log10(p).
doi:10.1371/journal.pone.0095558.g007
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Table 2. Effect sizes for the endpoints across all platforms.
Platform # Endpoint Description effect size
fMRI/memory 1 fMRI (retrieval,1) Ret: Hits v Correct rejections (Left hippocampus) 0.215
2 fMRI (retrieval,2) Ret: Hits v Correct rejections (Right hippocampus) 0.286
3 fMRI (retrieval,3) Ret: Hits v Misses (L HC) 0.228
4 fMRI (retrieval,4) Ret: Hits v Misses (R HC) 0.184
5 fMRI (encoding,1) Enc: Hits v Misses (L HC) 0.100
6 fMRI (encoding,2) Enc: Hits v Misses (R HC) 0.022
7 Memory (d-prime) d-prime 0.127
8 Memory (Hits) Hits (%) 0.224
9 Memory (FA) False alarms (%) 0.049
TMS 10 TMS (1) MEP amplitude mean (0–90 min) v baseline 0.188
11 TMS (2) MEP amplitude mean (0–30 min) v baseline 0.105
12 TMS (3) MEP amplitude mean (30–90 min) v baseline 0.263
cognition (CANTAB) 13 CANTAB: VRM (1) Verbal recognition memory, free recall total correct 0.011
14 CANTAB: VRM (2) VRM recognition (immediate) 0.014
15 CANTAB: VRM (3) VRM recognition (delayed) 0.155
16 CANTAB: PAL (1) Paired associates learning, total errors (6 shapes) 0.076
17 CANTAB: PAL (2) PAL total errors (8 shapes) 0.186
18 CANTAB: PAL (3) PAL total errors (adjusted) 0.101
19 CANTAB: CRT Choice reaction time, mean latency 0.211
20 CANTAB: IED (1) Intra/extra dimensional set shifting, EDS errors 0.063
21 CANTAB: IED (2) IED pre-ED errors 0.127
22 CANTAB: IED (3) IED stages completed 0.140
23 CANTAB: RVP Raid visual information processing, A-prime 0.079
24 CANTAB: SRT Simple reaction time, mean latency 0.071
25 CANTAB: SWM (1) Spatial working memory, between errors (6 boxes) 0.018
26 CANTAB: SWM (2) SWM between errors (8 boxes) 0.101
27 CANTAB: SWM (3) SWM within errors (6 boxes) 0.032
28 CANTAB: SWM (4) SWM within errors (8 boxes) 0.032
VMA 29 VMA (1) adapt mean angular error (blocks 2–10) 0.042
30 VMA (2) adapt mean ang error (blocks 11–19) 0.035
31 VMA (3) de-adapt mean ang error (blocks 2–10) 0.071
32 VMA (4) de-adapt mean ang error (blocks 11–19) 0.084
FLE 33 FLE (1) conditioning SCR to NS 0.226
34 FLE (2) conditioning SCR to CS 0.276
35 FLE (3) extinction SCR to CS 0.090
36 FLE (4) extinct-retention SCR to CS 0.076
EEG 37 EEG: MMN amplitude MMN difference wave amplitude 0.075
38 EEG: MMN latency MMN difference wave latency 0.080
39 EEG: Resting (1) Abs power (cent,alpha) 0.260
40 EEG: Resting (2) Abs power (cent,delta) 0.112
41 EEG: Resting (3) Abs power (cent,theta) 0.342
42 EEG: Resting (4) Abs power (front,alpha) 0.246
43 EEG: Resting (5) Abs power (front,delta) 0.062
44 EEG: Resting (6) Abs power (front,theta) 0.342
45 EEG: Resting (7) Abs power (par-occ,alpha) 0.169
46 EEG: Resting (8) Abs power (par-occ,delta) 0.137
47 EEG: Resting (9) Abs power (par-occ,theta) 0.337
48 EEG: Resting (10) Abs power (temp,alpha) 0.220
49 EEG: Resting (11) Abs power (temp,delta) 0.140
50 EEG: Resting (12) Abs power (temp,theta) 0.367
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polymorphism. Furthermore, and more interestingly, ACC grey
matter volume significantly predicted post-error slowing in the
flanker task in Met/Met subjects (and in the Met carriers
combined), but not in the Val/Val participants. The greater the
grey matter loss, the less the post-error slowing, hence less the
behavioural adaptation following errors. This finding provides a
clear link between structure and function involved in error
processing and monitoring behaviour. However, although both a
structural measure (ACC GM volume) and a functional measure
(delta band power) predict behavioural adaptation following
errors, ACC GM volume and delta band power were not
associated with each other. The lack of association could be
explained as follows. Among the several structural components
involved in the error processing network, ACC is only one, and
delta band EEG activity is a measure of the summation of the
activity of more than one structure in the brain. Hence, it is
possible that ACC GM volume in itself is not sufficient to explain
delta power changes in the flanker task.
Resting state EEG oscillations also emerged as markers that are
sensitive to the BDNF Val66Met polymorphism. An earlier study
[47] demonstrated increased slow-wave activity (theta, delta
frequency bands; 1.5–3.5 Hz and 4–7.5 Hz) and decreased fast-
wave activity (alpha frequency band; 8–13 Hz) in Met/Met
homozygotes over the whole scalp. We have also found increased
slow-wave activity (theta frequency band) in Met carriers when
compared to Val/Val homozygotes, over the whole head.
Increases in slow frequency oscillatory power has been though to
reflect inhibitory synaptic transmission within the cortico-thala-
mical circuits [68]. Imbalances of the cortical excitatory and
inhibitory mechanisms, reflected by altered EEG oscillations, have
been observed in neurodegenerative and psychiatric disorders. For
example, a shift in power from higher frequencies towards lower
frequencies has been found in Alzheimer’s disease [93] and in
Table 2. Cont.
Platform # Endpoint Description effect size
51 EEG: aLTP (1) aLTP post-tetanae mean v baseline N1 amplitude 0.003
52 EEG: aLTP (2) aLTP post-tetanae mean v baseline N1-P2 amp 0.131
53 EEG: P3a amplitude P3a peak amplitude 0.009
54 EEG: P3a latency P3a peak latency 0.085
55 EEG: P3b amplitude P3b AUC 0.047
56 EEG: P3b latency P3b peak latency 0.086
57 EEG: PE-slowing ERN: PE-slowing 0.250
58 EEG: ERN amplitude ERN: amplitude 0.150
59 EEG: ERN-error ampitude ERN: ampitude-error 0.097
60 EEG: ERN latency ERN: latency 0.070
61 EEG: ERN ERSP ERN: Event-related spectral perturbation 0.290
62 EEG: ERN-error ERSP ERN: ERSP-error 0.290
63 EEG: ERN PLF ERN: Phase-locking factor 0.260
64 EEG: ERN PLF-error ERN: PLF-error 0.400
VBM 65 VBM: LT ACC Grey matter volume (LT Anterior cingulate) 0.263
66 VBM: LB ACC Grey matter volume (LB Anterior cingulate) 0.158
67 VBM: RT ACC Grey matter volume (RT Anterior cingulate) 0.206
68 VBM: RB ACC Grey matter volume (RB Anterior cingulate) 0.183
69 VBM: Anterior cingulate DTI: Anterior cingulate grey matter volume 0.310
70 VBM: Prefrontal cortex DTI: Prefrontal cortex grey matter volume 0.220
DTI 71 DTI: L Arcuate Median FA (L Arcuate) 0.198
72 DTI: R Arcuate Median FA (R Arcuate) 0.096
73 DTI: L Cingulum Median FA (L Cingulum) 0.170
74 DTI: R Cingulum Median FA (R Cingulum) 0.192
75 DTI: Fornix Median FA (Fornix) 0.096
76 DTI: L ILF Median FA (L ILF) 0.208
77 DTI: R ILF Median FA (R ILF) 0.249
78 DTI: Splenium Median FA (Splenium) 0.199
79 DTI: L Uncinate Median FA (L Uncinate) 0.099
80 DTI: R Uncinate Median FA (R Uncinate) 0.008
Further details and p-values are reported elsewhere, see main text. Unresolved acronyms: TMS: Trans-cranial magnetic stimulation; MEP: Motor evoked potentials;
EDS:Extra-dimensional stage; pre-ED: Prior to the extra-dimesional shift; VMA: Visuomotor Association; FLE: Fear Learning and Extinction; SCR: Skin conductance
response; NS: Non-conditioned stimuli; CS: Conditioned Stimuli; MMN: Mismatch negativity; aLTP: auditory long-term potentiation; PE-slowing: Post-error slowing; ERN:
Error-related negativity; VBM: Voxel-based morphometry; LT: Left-top (superior); RB: Right-bottom (inferior); FA: Fractional anisotropy; ILF: Inferior longitudinal
Fasciculus.
doi:10.1371/journal.pone.0095558.t002
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depression [94]. Since BDNF has been shown to regulate
excitatory and inhibitory activity [5,48], the met allele, which
has been showed to be associated with suboptimal activity-
dependent BDNF secretion in the brain [27,28], could lead to an
imbalance in excitatory and inhibitory neural activity.
In comparison to ERN and resting EEG, we found no effect of
the BDNF polymorphism on other electrophysiological markers
including MMN and P300. Although MMN is a commonly used
electrophysiological marker in studies investigating various
psychiatric and neurodegenerative disorders, such as schizophre-
nia, Alzheimer’s and Parkinson’s disease (for reviews see [95,96]),
to our best knowledge MMN has not yet been investigated as a
function of allelic variation in BDNF gene polymorphisms. The
P300 ERP component was found to be sensitive to the
polymorphism in a previous study [29], but it could not be
replicated here. Both the MMN and P300 tap into cognitive
processes which are potentially affected by the BDNF polymor-
phism and which certainly are compromised in neurodegenerative
disorders. However, as noted earlier, findings regarding attention,
memory and executive functioning have been inconclusive [97]. It
is possible that the variability of these measures is more similar in
healthy met carriers and Val/Val subjects; hence these measures
are not consistent across different experiments and populations
and are not reliable markers of the polymorphism in healthy
participants.
The electrophysiological markers ERN and resting EEG,
accompanied with the grey matter volume of the anterior
cingulate, were found to be the most sensitive to the BDNF
polymorphism compared to other markers examined (see Figure 7
and Table 2). Effects sizes ranged from around 0.33 to 0.4 for
ERN/EEG, while other endpoints scarcely exceeded an effect size
of 0.2. For example, right hippocampal activity measured during a
memory task with fMRI is around 0.28; the strongest measures of
cortical excitability measured by tDCS or by various behavioural
measures of cognition (i.e. CANTAB tasks of attention, working
memory, learning, reaction time, and fear learning) are all below
0.28. These findings are reported separately and published
elsewhere [69,87].
In this study we also examined for the first time the effect of ‘met
allele load’ in a study that was prospectively designed with
approximately equal number of subjects in each genotype group.
Previous in vitro and in vivo animal studies have shown met allele
dependent effects where two met allele carriers were different from
those carrying one met allele in activity dependent BDNF release
and synaptogenesis [45,98,99], but the functional effects of met
allele load has not been systematically tested in humans. In this
study we observed in most cases no evidence for a met load effect
with the findings best explained by the met-dominant model; the
exceptions from this model were the behavioural results (post-error
slowing) and grey matter volume reductions in the ACC and PFC,
where a significant linear trend, i.e. significant stepwise effect of
‘met-load’, emerged. It is possible that impact of the met allele on
brain structure and/or function may be dependent on the level of
network complexity with greater effects on more explicit measures
(i.e. involving multiple brain areas to perform a behavioural
process), compared to implicit process (i.e. ERN and resting EEG).
This may explain the met allele load effect observed on ERN
related behavioural adaption and not the error related brain
activity. However findings from this study suggest that impair-
ments in synaptic activity could be measured in Met carriers and
having one or two copies of the allele does not impact on the
functional impairments.
There are some methodological factors that warrant discussion.
First we observed no significant effect of the polymorphism on
ERN amplitude (although a slight difference is visible in Figure 2),
while the effect was significant in the trial-by-trial power and
phase-locking data. A possible explanation for this discrepancy is
that ERP waveforms are the summation of signals across several
trials, hence peaks which vary in their timing from trial to trial are
prone to cancellation by the averaging procedure. Meanwhile, the
trial-by-trial data can be more sensitive since there is no
information loss due to averaging across trials. Second, we did
not measure a number of other ERPs relevant to neurodegener-
ative disorders (sensory evoked components, for example) and
hence it is possible that there are other EEG markers that may be
sensitive to the BDNF polymorphism. Finally we examined the
impact of the polymorphism at a single time point and it is possible
that the polymorphism may have greater effects on various
markers when examined longitudinally. Indeed, we have shown
larger effects of the BDNF polymorphism on declarative memory
and hippocampal volume loss when decline is examined over time
(i.e. 36 months) than at a single time point as reported in all
previous studies [34].
In summary, using the BDNF val66met polymorphism, we have
identified several electrophysiological markers that could sensi-
tively and reliably measure synaptic changes in the human brain.
The electrophysiological markers including ERN and resting EEG
theta power could be used as BDNF sensitive functional markers
in early clinical development to examine target engagement or
drug related efficacy of synaptic repair therapies. These findings
also provide some evidence for the successful use of a common
genetic polymorphisms in biomarker development.
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